Study details
Enrolling now
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder
Mclean Hospital
NCT IDNCT05837104ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 2.1 years
Ages
18–50
Locations
1 site in MA
About this study
Researchers are testing whether magnesium vitamin B6, combined with usual treatment, can help reduce symptoms of depression, stress, and anxiety in people experiencing their first episode of bipolar I disorder. The trial will last for 749 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Magnesium vitamin B6
- 2.Take Placebo
PhasePhase 2
DrugMagnesium vitamin B6
Routeoral
Primary goalChange in depressive symptoms
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Enzyme Interactions
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Change in depressive symptoms
Secondary: Change in adverse events, Change in anxiety symptoms, Change in stress symptoms
Body systems
Psychiatry / Mental Health